|
Dr. D'Addario was born in 1967 and
completed his medical school at the University of Basel, Switzerland, in 1992.
He was trained in Internal Medicine in Langenthal and at the Inselspital in Bern, Switzerland,
where he initiated his education in medical oncology.
He then served as a senior staff member at
the Department of Medical Oncology of the Kantonsspital St.Gallen, specializing
in thoracic malignancies and in brain tumors. During this period, Dr. D'Addario
visited the Princess Margaret Hospital
in Toronto, Canada, where he conducted a
meta-analysis on the use of platinum compounds in non-small-cell lung cancer
treatment. He is involved in national and international clinical trials and is
an active member and principal investigator of the lung cancer group of the
Swiss Group of Clinical Cancer Research (SAKK). His main scientific interest concerns
the optimal use of tyrosine kinase inhibitors in lung cancer therapy.
Since 2007, he serves as an active member
of the ESMO Examination Working Group. Also in 2007, he co-founded the
Onkologie Schaffhausen, a private cancer center in Schaffhausen, Switzerland,
linked to the SAKK network and to the Kantonsspital Schaffhausen.
|
